您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > ML351
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
ML351
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
ML351图片
CAS NO:847163-28-4
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
ML351 是一种有效且高度特异性的 15-LOX-1 抑制剂，IC50 为 200 nM。
Cas No.847163-28-4
别名CID 664510
化学名5-(methylamino)-2-(1-naphthalenyl)-4-oxazolecarbonitrile
Canonical SMILESCNC1=C(C#N)N=C(O1)C2=C3C(C=CC=C3)=CC=C2
分子式C15H11N3O
分子量249.3
溶解度≤5mg/ml in DMSO; 25mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

ML351 is a potent and selective inhibitor of human 15-lipoxygenase-1 with IC50 value of 200 nM [1][2].

Human lipoxygenases (LOX) are nonheme iron-containing enzymes that catalyze the dioxygenation of polyunsaturated fatty acids (e.g., linoleic acid (LA) and arachidonic acid (AA)) to form hydroperoxy fatty acids [1][2]. Human reticulocyte 15-lipoxygenase-1 is an attractive therapeutic target for its role in atherogenesis, diabetes, Alzheimer’s disease, new-born periventricular leukomalacia, breast cancer, and stroke [2].

ML351 is a potent and selective 15-lipoxygenase inhibitor. ML351 exhibited nanomolar potency and excellent selectivity (>250-fold) versus 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2. In mouse neuronal HT22 cells, ML351 dose-dependently protected against oxidative glutamate toxicity and completely reversed the increase in 12-HETE following glutamate treatment [2][3].

In permanent focal ischemia mice model, IP administration of ML351 resulted in a ~30% reduction in infarct size [2][3].

References:
[1]. Rai G, Joshi N, Perry S, et al. Discovery of ML351, a Potent and Selective Inhibitor of Human 15-Lipoxygenase-1. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-2013 Apr 15 [updated 2014 Jan 13].
[2]. Rai G, Joshi N, Jung JE, et al. Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. J Med Chem. 2014 May 22;57(10):4035-48.
[3]. Gaffney BJ. Lipoxygenases: structural principles and spectroscopy. Annu Rev Biophys Biomol Struct. 1996;25:431-59.